News | 16 July 2012
LONDON (Reuters) - GlaxoSmithKline chief executive Andrew Witty has an eye for a bargain. Despite paying a 99 percent premium for Human Genome Sciences, he is still getting the biotechnology company for less than half what it was worth 14 months ago.
Click on the link to read the full article at Reuters UK
(This link will open in a new window)